Skip to content

A prospective cohort study of laparoscopic mediastinal lymph node dissection through esophageal hiatus and thoracic pathways for Siewert type II esophageal gastric junction adenocarcinoma

A prospective cohort study of laparoscopic mediastinal lymph node dissection through esophageal hiatus and thoracic pathways for Siewert type II esophageal gastric junction adenocarcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078636
Enrollment
Unknown
Registered
2023-12-14
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Siewert type II esophageal gastric junction adenocarcinoma

Interventions

Transesophageal hiatal pathway group:NA
Transthoracic pathway group:NA

Sponsors

Handan Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 18 years old = Age = 75 years old; 2. Preoperative pathological diagnosis of adenocarcinoma; 3. The tumor center is located within a range of 1cm on the dentate line to 2cm below the dentate line (as seen by gastroscopy, CT, and postoperative specimens), which is Siewert II type esophageal gastric junction adenocarcinoma; 4. Esophageal invasion<3cm; 5. The tumor T stage is T2-T4a; 6. Able to achieve radical resection; 7. Sign informed consent form

Exclusion criteria

Exclusion criteria: 1. Severe heart, lung, liver, and kidney dysfunction, unable to tolerate surgery; 2. Preoperative detection of distant organ metastasis; 3. During surgery, tumor invasion of surrounding tissues and organs or peritoneal metastasis (M1) was found; 4. Merging malignant tumors of other organs; 5. Missing clinical data; 6. Expected inability to cooperate in completing follow-up

Design outcomes

Primary

MeasureTime frame
Local recurrence rate after treatment in each group of patients;

Secondary

MeasureTime frame
Long term survival rate of patients in each group;Total survival time of patients in each group;

Countries

China

Contacts

Public ContactWang Yuhong

Handan Central Hospital

1819115973@qq.com+86 131 3100 6055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026